camptothecin has been researched along with nb 506 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (88.89) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanzawa, F; Kubota, N; Nishio, K; Saijo, N | 1 |
| Arioka, H; Bojanowski, K; Fukuda, M; Ishida, T; Kanzawa, F; Nishio, K; Ogasawara, H; Oka, M; Saijo, N | 1 |
| Fukasawa, K; Hara, Y; Komatani, H; Nishimura, S; Okura, A; Suda, H; Yoshinari, T | 1 |
| Saijo, N | 1 |
| Harstrick, A; Hilger, RA; Rustum, YM; Seeber, S; Vanhoefer, U; Voigt, W; Yin, MB | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Fukasawa, K; Komatani, H; Morita, M; Nishimura, S; Okura, A; Sakaizumi, N; Yoshida, E; Yoshinari, T | 1 |
| Bailly, C; Carrasco, C; Hamy, F; Prudhomme, M; Rubin, E; Saleem, A; Vezin, H | 1 |
| Bailly, C; Kohlhagen, G; Laco, G; Pommier, Y; Takebayashi, Y; Urasaki, Y | 1 |
1 review(s) available for camptothecin and nb 506
| Article | Year |
|---|---|
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
8 other study(ies) available for camptothecin and nb 506
| Article | Year |
|---|---|
Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.
Topics: Antineoplastic Agents; Camptothecin; Carbazoles; Carcinoma, Small Cell; Cell Nucleus; Drug Resistance; Glucosides; Humans; In Vitro Techniques; Irinotecan; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1995 |
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carbazoles; Carcinoma, Small Cell; Cell Division; Cell Nucleus; Cell Survival; Cisplatin; DNA Repair; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Glucosides; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1996 |
Sequence-selective DNA cleavage by a topoisomerase I poison, NB-506.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Carbazoles; DNA; DNA Repair; Glucosides; Molecular Sequence Data; Topoisomerase I Inhibitors | 1998 |
Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multid
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blotting, Northern; Camptothecin; Carbazoles; Cell Count; Chromatography, High Pressure Liquid; DNA Topoisomerases, Type I; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fibrosarcoma; Glucosides; Humans; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1997 |
[NB 506].
Topics: Animals; Antineoplastic Agents; Camptothecin; Carbazoles; Clinical Trials, Phase I as Topic; Drug Resistance; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Glucosides; Humans; Neoplasms; Topoisomerase I Inhibitors | 1999 |
A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carbazoles; DNA Damage; DNA Topoisomerases, Type I; DNA, Complementary; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Rearrangement; Glucosides; Humans; Leukemia P388; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors | 1999 |
The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Topics: Amino Acid Substitution; Aminoglycosides; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Base Sequence; Binding Sites; Camptothecin; Carbazoles; DNA Damage; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glucosides; Humans; Indoles; Intercalating Agents; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenylalanine; Recombinant Proteins; Serine; Topoisomerase I Inhibitors | 1999 |
Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Topics: Antineoplastic Agents; Binding Sites; Camptothecin; Carbazoles; Cell Survival; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glucosides; Humans; Intercalating Agents; Mutation; Stereoisomerism; Tumor Cells, Cultured | 2001 |